Verrica Pharmaceuticals Inc

This advisory (non-binding) proposal asks stockholders to approve, on a say-on-pay basis, the disclosed compensation of Verrica’s named executive officers for 2026. Management frames the vote as an overall endorsement of the company’s compensation philosophy and the specific pay arrangements disclosed in the proxy, arguing that pay is market-competitive and aligned with stockholder interests through a mix of salary, annual incentives and equity awards. The vote is non-binding, but the Board and Compensation Committee state they will take the outcome into account when making future pay decisions, which creates reputational and governance pressure on management to respond to negative outcomes. Key contextual factors include the company’s use of equity to attract and retain talent in the life sciences sector, discretionary bonus payments in 2025, and recent grants that include performance- or market-priced vesting conditions contingent on stockholder approval of the equity plan (Proposal 4). From a governance perspective, the company discloses engagement with a compensation consultant and policies (e.g., clawback compliance and committee independence) that it uses to justify its approach. A vote against would signal shareholder dissatisfaction and could prompt the Compensation Committee to revisit pay practices or disclosure; a vote for maintains the status quo. The Company’s recommendation to vote for the proposal reflects management’s view that the program supports retention and long-term alignment, but investors should weigh potential dilution from equity grants and the non-binding nature of the vote when assessing governance risk. Overall, the proposal presents a routine governance checkpoint that allows investors to express support or concern about executive pay without forcing immediate contractual change.

This management proposal requests shareholder approval to amend and restate the company’s 2018 equity plan to expand the share reserve and adjust the mechanics of the annual share-refresh. The Amended 2018 Plan would increase the initial share reserve to 4,000,000 shares, set an aggregate ISO exercise cap of 12,000,000 shares, and change the automatic annual refresh from 4% to 5% of outstanding shares (and explicitly include shares issuable upon settlement of pre-funded warrants in the refresh calculation). Management argues the changes are needed to preserve the company’s ability to grant equity awards used for recruiting and retention in the competitive life sciences sector, and to ensure the share pool reflects shares that will enter outstanding upon conversion of pre-funded warrants issued in recent financings. The proxy discloses that, if approved, approximately 2.76 million shares would remain available for issuance immediately after the meeting, and notes that certain awards approved in December 2025 are contingent on stockholder approval of this increase—linking the vote to near-term grant realizations. The Board recommends approval and acknowledges potential director and executive benefits from the plan, recognizing conflicts of interest; it frames approval as necessary for ongoing operations and talent management. Key governance considerations for sophisticated investors include dilution (the increased reserve and larger annual refresh increase share issuance capacity), the particulars of recycling forfeited or repurchased shares, non-employee director annual compensation caps, repricing authority, and change-in-control treatment. The inclusion of pre-funded warrants in the refresh calculation reflects management’s attempt to neutralize the dilutive timing mismatch created by issuing pre-funded warrants in recent financings, but investors should evaluate the arithmetic effect on future dilution. Finally, because the Board and Compensation Committee administer awards and stand to benefit, investors should weigh the adequacy of guardrails (e.g., limits on director awards, clawback policy, and committee independence) when assessing whether the plan’s expanded capacity is justified.